AstraZeneca, Amgen Score Phase 3 Win in Debilitating Swallowing Disease
In brief
Tezspire’s Phase 3 win positions it as the first approved treatment for EoE, potentially opening a sizable new market for AstraZeneca and Amgen.
ClearTape summarizes context in-app. For the full publisher article, use Read original source above.